After Morgan Stanley and Cowen & Co. gave Alexion Pharmaceuticals (NASDAQ: ALXN) a Buy rating last month, the company received another Buy, this time from William Blair. Analyst Raju Prasad maintained a Buy rating on Alexion Pharmaceuticals today. The company’s shares closed last Monday at $98.41, close to its 52-week low of $92.56.
According to TipRanks.com, Prasad is a 4-star analyst with an average return of 8.7% and a 48.4% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Allogene Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alexion Pharmaceuticals with a $156.21 average price target, representing a 55.8% upside. In a report issued on October 11, Morgan Stanley also maintained a Buy rating on the stock with a $170.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $141.86 and a one-year low of $92.56. Currently, Alexion Pharmaceuticals has an average volume of 2.35M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P.
